文献速递白血病

大剂量甲氨蝶呤治疗显著改善成人急性淋巴细胞白血病生存:JALSG的III期研究

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.
PubMed 文献 · Leukemia · 2017-09-15

本研究为JALSG开展的随机III期试验,纳入25至64岁费城染色体阴性成人急性淋巴细胞白血病患者,比较含大剂量甲氨蝶呤(3 g/m2)方案与中剂量甲氨蝶呤(0.5 g/m2)方案。完全缓解率为86%,大剂量组5年无病生存率58%,显著优于中剂量组的32%(P=0.0218),严重不良事件频率无显著差异。

要点

  • 大剂量甲氨蝶呤组5年无病生存率58%,显著优于中剂量组32%(P=0.0218)。
  • 两方案严重不良事件频率无显著差异。
  • 结果为大剂量甲氨蝶呤方案用于成人费城染色体阴性急性淋巴细胞白血病提供依据。

核心结论

  • 研究证明大剂量甲氨蝶呤方案治疗成人费城染色体阴性急性淋巴细胞白血病有效且安全。
  • 研究结果为含大剂量甲氨蝶呤方案用于成人急性淋巴细胞白血病治疗提供了有力依据。

研究设计与样本

  • 随机III期试验,比较含大剂量甲氨蝶呤方案与含中剂量甲氨蝶呤方案。
  • 研究在UMIN-CTR注册(ID: C000000063)。
  • 纳入25至64岁费城染色体阴性急性淋巴细胞白血病患者,共360例入组。
  • 达到完全缓解的患者随机分配接受含大剂量甲氨蝶呤(3 g/m2)或中剂量甲氨蝶呤(0.5 g/m2)的方案。
  • 大剂量甲氨蝶呤组115例,中剂量甲氨蝶呤组114例。

主要发现

  • 完全缓解率为86%。
  • 大剂量甲氨蝶呤组估计5年无病生存率为58%,中剂量甲氨蝶呤组为32%,大剂量组显著优于中剂量组(P=0.0218)。
  • 严重不良事件频率无显著差异。

关键数值与推荐

  • 大剂量甲氨蝶呤剂量为3 g/m2,中剂量甲氨蝶呤剂量为0.5 g/m2。
  • 大剂量甲氨蝶呤组估计5年无病生存率58%,中剂量甲氨蝶呤组32%(P=0.0218)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-dose methotrexate (Hd-MTX) therapy has recently been applied to the treatment of adult acute lymphoblastic leukemia (ALL) based on pediatric protocols; however, its effectiveness for adult ALL has not yet been confirmed in a rigorous manner. We herein conducted a randomized phase III trial comparing Hd-MTX therapy with intermediate-dose (Id)-MTX therapy. This study was registered at UMIN-CTR (ID: C000000063). Philadelphia chromosome (Ph)-negative ALL patients aged between 25 and 64 years of age were enrolled. Patients who achieved complete remission (CR) were randomly assigned to receive therapy containing Hd-MTX (3 g/m2) or Id-MTX (0.5 g/m2). A total of 360 patients were enrolled. The CR rate was 86%. A total of 115 and 114 patients were assigned to the Hd-MTX and Id-MTX groups, respectively. The estimated 5-year disease-free survival rate of the Hd-MTX group was 58%, which was significantly better than that of the Id-MTX group at 32% (P=0.0218). The frequencies of severe adverse events were not significantly different. We herein demonstrated the effectiveness and safety of Hd-MTX therapy for adult Ph-negative ALL. Our results provide a strong rationale for protocols containing Hd-MTX therapy being applied to the treatment of adult ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sakura T, Hayakawa F, Sugiura I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2017. PMID: 28914260. doi:10.1038/leu.2017.283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。